For example, a clinical trial of paclitaxel with or without olaparib in second-line treatment of advanced metastatic gastric cancer examined reduced ATM expression, defined as less than 25% tumor cells staining positive in an immunohistochemistry assay, as a marker of benefit [81]. Here, ATM is linked to neoplasm.